# Patient Oriented Research in Personalized Antithrombotic Therapy

> **NIH NIH K24** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2020 · $118,384

## Abstract

Abstract
Nita Limdi, Pharm.D, PhD has built a successful research program focused on antithrombotic therapy
pharmacogenomics encompassing both observational and clinical trial designs. Her scientific career goals
are to comprehensively understand the clinical, environmental and genetic factors that influence variability
in antithrombotic response and to use this information to personalize antithrombotic treatment, especially in
patients with multiple comorbidities. The proposed award would enable her to continue mentoring while
augmenting her research, specifically incorporating aims built to address key knowledge gaps regarding the
oral anticoagulant and antiplatelet therapy.
The new research proposed herein is builds on ongoing work to create unique and much needed patient
oriented research (POR) training opportunities within the evolving landscape of oral antithrombotic therapy
and integrates pharmacogenomics and implementation of precision medicine. The candidate's NHLBI R01
grant along with the three new projects will form the basis for the mentee training. Each project is led by a
mentee. PROJECT1 will elucidate the influence of heart failure as defined as left ventricular ejection fraction
(LVEF <40%) on warfarin response. PROJECT 2: will evaluate the influence of clinical and genetic
(candidate genes) on Dabigatran (DBG) related hemorrhage and build clinical prediction rules to
personalize the prediction of hemorrhage among DBG users. PROJECT 3: will evaluate the effectiveness of
genotype-guided antiplatelet therapy (GGAT) on complications following percutaneous coronary
intervention and assess its clinical utility and economic value.
Mentorship aims expanding the POR training opportunities for MD, Pharm.D, and PhD trainees. Mentees
will lead the new projects, conduct analysis and publish original research. They will leverage this to propose
new research as part of their NIH- K23 applications.
In the strongly supportive and collaborative environment of UAB, this award will ensure Dr. Limdi continues
to grow her research program, and build capacity in POR by mentoring junior investigators to build their own
careers. The breadth and depth of the multiple institutional programs, UAB's CTSA and her leadership in
UAB's Personalized Medicine Institute will provide the resources and the foundation to advance precision
cardiovascular medicine.

## Key facts

- **NIH application ID:** 9986870
- **Project number:** 5K24HL133373-05
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** NITA A LIMDI
- **Activity code:** K24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $118,384
- **Award type:** 5
- **Project period:** 2016-08-01 → 2021-07-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9986870

## Citation

> US National Institutes of Health, RePORTER application 9986870, Patient Oriented Research in Personalized Antithrombotic Therapy (5K24HL133373-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9986870. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*